Finally, two newer compounds that we developed, a pan-glutaminase inhibitor SU1 and a GLS-selective compound UP4, were tested against SARS-CoV-2-induced morbidity and mortality in the K18-hACE2 transgenic mice model, where they were shown to significantly reduce infection while extending the survival of these animals. The gene discussed is GLS; the disease is infection.